In the News: Lipokinetix and Hepatitis

In the News: Lipokinetix and Hepatitis

The Food and Drug Administration (FDA) is urging consumers to discontinue use of the dietary supplement Lipokinetix®, which has been associated with multiple reports of hepatitis and hepatic failure.

Marketed by Syntrax Innovations, Inc. for weight loss, Lipokinetix contains phenylpropanolamine (norephedrine), caffeine, yohimbine (Pausinystalia johimbe), diiodothyronine, and sodium usniate. The injuries reported to the FDA occurred in persons ages 20-32 years; liver injury developed after 2-12 weeks of Lipokinetix use. No other apparent causes of liver injury were identified in these reports.